The Proton Pump Inhibitors (PPIs) Market is being driven by Reformulation of drugs
The Proton Pump Inhibitors (PPIs) Market is expected to grow at a CAGR of 4.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 819.5 million. In the aging population, the prevalence of gastroesophageal reflux disease (GERD) and associated symptoms such as heartburn increases due to the relaxation of the lower esophageal sphincter and the slowing down of the digestive system. This relaxation allows stomach acid to reflux, leading to discomfort and potential health issues. Proton Pump Inhibitors (PPIs) are an effective treatment for acid-related disorders, making the aging demographic a significant growth driver for the global PPIs market. The market is poised to expand as the population ages and the prevalence of related disorders rises.
Get more information on Proton Pump Inhibitors (PPIs) Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
199 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.7% |
|
Market growth 2025-2029 |
USD 819.5 million |
|
Market structure |
market_structure.ucfirst |
|
YoY growth 2024-2025(%) |
4.4 |
|
Key countries |
US, Germany, China, Canada, UK, India, France, Japan, Brazil, and UAE |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
Proton Pump Inhibitors (PPIs) are a type of acid-suppressing medication used to treat various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and heartburn. These disorders are caused by excessive stomach acid production, which can be triggered by poor dietary choices, sedentary work cultures, stress, and aging. The gastric proton pump is the target of these medications, reducing acid secretion and promoting gastrointestinal health. Drug formulations like Lansoprazole, Esomeprazole, Rabeprazole, Dexlansoprazole, and Pantoprazole are available in both over-the-counter (OTC) and prescription forms to cater to personalized medicine approaches. Healthcare investment in pharmaceutical solutions for acid-related disorders continues to grow, addressing the needs of an aging population.
The Proton Pump Inhibitors (PPIs) market is a significant segment within the larger global pharmaceuticals industry. This market encompasses entities involved in the research and development (R&D) or production of various drug formulations, including generic and non-generic medications, as well as veterinary drugs. According to Technavio's market analysis, the healthcare sector's overall growth is driven by factors such as an aging population. By 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old, leading to a surge in demand for treatments related to acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers. These conditions are characterized by excessive stomach acid production, which can be regulated through the inhibition of the gastric proton pump. Consequently, the market for PPIs, which are among the most effective acid-suppressing medications, is poised for substantial growth.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
